Should oral contraceptive users be screened for factor V Leiden?

BMJ

Volumn 315, Issue 7099, 1997, Pages 60-

  Ward, Tim ^a   Vandenbroucke, J P ^b  

^a French Weir Health Centre   (United Kingdom)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 5 LEIDEN; GESTAGEN; ORAL CONTRACEPTIVE AGENT; PROGESTERONE;

DRUG EFFICACY; EDUCATION; FEMALE; HUMAN; INTRAUTERINE CONTRACEPTIVE DEVICE; LETTER; LUNG EMBOLISM; MENSTRUAL IRREGULARITY; MOTIVATION; ORAL CONTRACEPTION; PRIORITY JOURNAL; RISK; SCREENING; THROMBOGENESIS;

CONTRACEPTIVES, ORAL; FACTOR V; FEMALE; HUMANS; THROMBOSIS;

EID: 0030976307     PISSN: 09598138     EISSN: 14685833     Source Type: Journal    
DOI: 10.1136/bmj.315.7099.60     Document Type: Letter

References (1)

1. Vandenbroucke JP, van der Meer FJM, Helmerhorst FM, Rosendaal FR. Factor V Leiden: should we screen oral contraceptive users and pregnant women BMJ 1996; 313: 1127–30. (2 November.)